Skip to contentB
Biolargo, Inc.
B
BLGOBiolargo, Inc. Q2 2023 · 10-Q
Revenue$1.45M$1.45M+9.3% vs Q2 2022 Net Income-$1.63M-$1.63MN/M vs Q2 2022 EPS, diluted—
Gross Profit$819,000+31.5% Operating Income-$1,559,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Biolargo, Inc. · CIK 880242 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,484,000N/M Margins · derivedGross margin56.6%+9.5 pt vs Q2 2022
Operating margin-107.8%−8.0 pt vs Q2 2022
Net margin-112.4%−11.7 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 14, 2023 · 45 d after period end